List of Excipients in Branded Drug REYVOW

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	REYVOW	lasmiditan	0002-4312	CELLULOSE, MICROCRYSTALLINE	2040-07-06
Eli Lilly and Company	REYVOW	lasmiditan	0002-4312	CROSCARMELLOSE SODIUM	2040-07-06
Eli Lilly and Company	REYVOW	lasmiditan	0002-4312	FERROSOFERRIC OXIDE	2040-07-06
Eli Lilly and Company	REYVOW	lasmiditan	0002-4312	MAGNESIUM STEARATE	2040-07-06

REYVOW Excipient Strategy and Commercial Opportunities for Lasmiditan

Last updated: September 4, 2026

REYVOW (lasmiditan) is an oral 5-HT1F receptor agonist approved by the FDA for the acute treatment of migraine with or without aura in adults. Its commercial opportunity is concentrated in differentiated oral delivery, tolerability management, generic lifecycle strategy, and excipient changes that improve usability without changing the active pharmaceutical ingredient (API). The marketed product is a film-coated immediate-release tablet in 50 mg and 100 mg strengths. Public labeling identifies lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, and magnesium stearate among the tablet excipients.[1]

Lasmiditan’s principal formulation constraint is pharmacodynamic rather than chemical. The drug is associated with central nervous system adverse effects, including dizziness and sedation, and patients are instructed not to drive or operate machinery for at least eight hours after dosing.[1] A successful excipient strategy therefore needs to improve dose convenience, tablet robustness, onset consistency, and patient acceptability without creating a faster or more intense CNS exposure profile.

What excipients are used in REYVOW tablets?

REYVOW is an immediate-release, film-coated oral tablet. The FDA prescribing information identifies the following core excipients:[1]

Excipient	Likely functional role	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Creates an opportunity for lactose-free or low-lactose line extensions
Microcrystalline cellulose	Filler, dry binder, and disintegration support	Supports direct compression and tablet mechanical strength
Pregelatinized starch	Binder and disintegrant	Helps balance hardness with rapid breakup
Croscarmellose sodium	Superdisintegrant	Important for immediate-release dissolution
Magnesium stearate	Lubricant	Excess levels can slow wetting and dissolution
Film-coating system	Appearance, swallowability, moisture and handling protection	Potential area for color, opacity, polymer, and coating-process differentiation

The formulation is conventional for an immediate-release tablet. That lowers manufacturing complexity and supports generic development. It also limits the amount of defensible product differentiation available from the existing dosage form.

What formulation attributes matter most?

For lasmiditan, the target product profile should prioritize:

1. Rapid and reproducible disintegration.
2. Dissolution consistency across pH conditions.
3. Low tablet weight and acceptable swallowability.
4. Sufficient mechanical strength for commercial packaging.
5. Low sensitivity to magnesium stearate over-lubrication.
6. Stability under standard room-temperature storage.
7. Minimal impact on the rate and extent of lasmiditan absorption.

Lasmiditan has high oral bioavailability, reported at approximately 40%, with a median time to maximum plasma concentration of about 1.8 hours.[1] A formulation that substantially accelerates absorption could alter tolerability, even if total exposure remains comparable. For that reason, a fast-dissolving product is commercially attractive, but a highly supersaturating or absorption-enhancing system could increase regulatory and clinical risk.

Which excipient strategies create commercial opportunities for REYVOW?

The strongest opportunities are lactose-free tablets, orally disintegrating tablets, oral films, dose-flexible products, and patient-friendly packaging. Each option has a different regulatory and intellectual-property profile.

Lactose-free or low-lactose REYVOW

The current tablet uses lactose monohydrate. A lactose-free version could replace lactose with one or more of the following:

• Mannitol
• Anhydrous dibasic calcium phosphate
• Spray-dried microcrystalline cellulose
• Co-processed cellulose-silica systems
• Isomalt
• Low-substituted hydroxypropyl cellulose

Mannitol is commercially attractive because it has a clean mouthfeel and supports orally disintegrating formats. It can, however, produce brittle tablets or require tighter control of compression and lubricant levels. Dibasic calcium phosphate improves hardness but may alter dissolution behavior and tablet density.

A lactose-free product would probably have limited standalone market power unless linked to a broader patient-convenience claim. Its strongest commercial use may be as a generic differentiation strategy or as part of a reformulated product for patients who avoid lactose-containing excipients.

Orally disintegrating tablets

An orally disintegrating tablet could reduce the need for water and improve administration during an acute migraine attack. Suitable excipient systems may include:

• Mannitol as a bulk sweetener and diluent
• Crospovidone or croscarmellose sodium as a superdisintegrant
• Low-moisture microcrystalline cellulose
• Colloidal silicon dioxide as a flow aid
• Aspartame, sucralose, or other taste-masking agents
• Flavor systems compatible with lasmiditan’s bitterness
• Magnesium stearate or sodium stearyl fumarate at controlled concentrations

The primary development challenge is taste. Lasmiditan’s dose, particularly at 100 mg, may create a substantial taste-masking burden. Direct compression could produce a bulky tablet, while lyophilized tablets may improve disintegration but have lower mechanical strength and higher packaging costs.

A successful ODT would need to demonstrate acceptable in vitro disintegration, dissolution, stability, dose uniformity, and taste. If the product is intended to support an abbreviated regulatory pathway, the sponsor must preserve bioequivalence to the reference product. A marked change in absorption rate could require additional clinical work.

Oral thin film

An oral film could deliver lasmiditan without swallowing a conventional tablet. Commercial advantages include portability, water-free administration, and a lower visual burden than a bottle of tablets.

The technical barriers are material loading, dose uniformity, moisture sensitivity, film flexibility, and taste. A 100 mg dose is high for many thin-film platforms. A multilayer film or high-solids matrix may be required, which can reduce flexibility and increase manufacturing complexity.

Film-forming polymers could include hydroxypropyl methylcellulose, pullulan, polyvinyl alcohol, or maltodextrin-based systems. Plasticizers such as polyethylene glycol or glycerol can improve flexibility but may increase moisture uptake. Taste masking would likely require polymeric complexation, ion exchange, or a coated API intermediate.

An oral film would have stronger commercial differentiation than a lactose-free tablet, but it would also face a higher formulation and regulatory burden.

Modified-release or pharmacokinetic control

Modified release is less attractive for acute migraine than immediate release. The clinical objective is prompt relief, and prolonging exposure could extend dizziness or sedation. An extended-release product may have utility only for a different indication or a specific patient population. It would not be a straightforward line extension of the approved acute-treatment product.

A more realistic approach is controlled disintegration or dissolution rather than true extended release. The sponsor could target consistent exposure across fed and fasted states while avoiding a sharp increase in peak concentration.

How does REYVOW compare with competing migraine drugs?

REYVOW competes with triptans, gepants, and nonprescription analgesics. Its commercial positioning depends partly on patients for whom vasoconstrictive mechanisms are undesirable or triptans are ineffective.

Product class	Representative products	Formulation position	Key competitive issue
Lasmiditan	REYVOW	50 mg and 100 mg immediate-release tablets	CNS effects and eight-hour driving restriction
Triptans	Sumatriptan, rizatriptan, eletriptan	Tablets, ODTs, nasal sprays, injections	Established use, low cost, but vascular restrictions
Gepants	Ubrogepant, rimegepant, zavegepant	Tablets, ODT, nasal spray	Strong convenience competition and expanding preventive use
NSAIDs and analgesics	Ibuprofen, naproxen, acetaminophen combinations	Broad oral and nonoral availability	Low cost and easy access

Gepants pose the most direct branded competitive pressure because they are also positioned as non-vasoconstrictive acute migraine therapies. Rimegepant has an ODT format, and zavegepant has a nasal spray, giving those products delivery-system advantages over a conventional tablet.[2,3]

REYVOW’s strongest segment is likely patients who need a non-triptan acute therapy and accept the driving restriction. Excipient innovation should focus on administration during migraine attacks rather than on creating a general-purpose daily product.

What FDA regulatory pathway applies to REYVOW formulation changes?

REYVOW was approved under NDA 211280 in October 2019.[4] A new lasmiditan formulation can follow different FDA pathways depending on the sponsor’s relationship to the reference product and the extent of the change.

505(b)(2) pathway

A materially different dosage form, such as an ODT, oral film, or nasal formulation, would generally be a 505(b)(2) candidate. The sponsor could rely partly on FDA findings for lasmiditan while providing new data for formulation performance, pharmacokinetics, safety, and possibly efficacy.

A 505(b)(2) product may receive three years of regulatory exclusivity for a new clinical investigation essential to approval. New patents covering the formulation, manufacturing process, or method of use may also be listed in the Orange Book if they meet FDA requirements.

ANDA pathway

A conventional generic tablet would ordinarily use the ANDA pathway. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to REYVOW. Different inactive ingredients are generally permissible, but the applicant must meet FDA requirements for safety, quality, labeling, and comparative performance.

Excipient substitution is most commercially useful in an ANDA when it enables:

• Lower manufacturing cost
• Improved stability
• Removal of an allergen or intolerance concern
• Better tablet robustness
• Lower tablet weight
• More efficient packaging
• Reliable dissolution across manufacturing sites

What patents protect REYVOW and its formulation?

The relevant intellectual-property categories are the lasmiditan compound, pharmaceutical compositions, therapeutic uses, polymorphs or salts, and manufacturing processes. The FDA Orange Book and USPTO records are the controlling sources for current U.S. patent listings and legal status.[5,6]

The original composition-of-matter estate is the most important barrier because it can delay ordinary generic entry even when the marketed tablet formulation is conventional. Formulation patents are commercially weaker if they claim routine excipient combinations without a demonstrated technical effect. Claims directed to a specific dissolution profile, stability improvement, particle engineering method, or clinically relevant pharmacokinetic result are more defensible.

How strong is the formulation patent estate?

The formulation estate should be assessed against five factors:

Factor	Strong position	Weak position
Claim scope	Defined composition or process with measurable limits	Broad routine excipient list
Technical effect	Demonstrated stability, dissolution, or bioavailability advantage	No comparative performance data
Enablement	Multiple examples across strengths and scales	Single laboratory example
Design-around risk	Narrow substitution options	Easy replacement of filler or disintegrant
Litigation value	Claim maps to commercial product	Claim covers only a nonessential variant

A generic applicant can often design around a conventional excipient claim by replacing the filler, disintegrant, lubricant, or coating polymer. Claims tied to a specific API particle size, solid form, manufacturing step, or dissolution profile may present a greater barrier.

What is the Orange Book and Paragraph IV risk for REYVOW?

An ANDA applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. The patent holder can file infringement litigation within 45 days, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[7]

The practical generic-entry scenarios are:

Scenario	Likely commercial effect
No listed patent barrier	Approval can proceed after regulatory requirements are satisfied
Paragraph III certification	Approval is deferred until patent expiration
Paragraph IV challenge with litigation	Approval may be delayed by litigation and a 30-month stay
Settlement with licensed entry	Entry date depends on settlement terms
Formulation design-around	Generic may avoid some formulation claims while contesting core patents
Authorized generic	Price erosion can begin before independent generic launch

Public company filings should be reviewed for any disclosed REYVOW patent litigation, settlement, or royalty arrangement. Lilly does not generally report REYVOW revenue as a separately disclosed major product line in its consolidated public reporting, limiting precision in estimating brand revenue exposure.[8]

Which licensing and partnering opportunities exist?

Potential partners include generic manufacturers, specialty migraine companies, oral-film developers, ODT technology licensors, and contract development and manufacturing organizations.

The most credible deal structures are:

• A 505(b)(2) license for an ODT or oral film
• A regional commercialization agreement for a reformulated tablet
• An excipient or co-processed excipient supply agreement
• A generic development collaboration
• A technology license covering taste masking or rapid disintegration
• A contract manufacturing agreement with milestone-based scale-up payments

A partner would likely value a formulation that demonstrates bioequivalence, improves patient use, and avoids dependence on a proprietary excipient supplier. Exclusivity should be tied to defined territories, dosage forms, regulatory milestones, and minimum commercial commitments.

What manufacturing and geographic barriers affect REYVOW opportunities?

Immediate-release tablets have relatively low manufacturing barriers. Commercial advantages may come from scale, quality systems, API sourcing, and regulatory documentation rather than complex equipment.

A reformulated product may face higher barriers in:

• Taste-masking intermediate manufacture
• Low-moisture ODT compression
• Film casting and drying
• Content-uniformity control at high API loading
• Stability packaging
• Scale-up from laboratory to commercial equipment
• Supplier qualification for specialty excipients

U.S. opportunities are shaped by Orange Book patents, FDA exclusivity, and Hatch-Waxman litigation. European opportunities depend on national and centralized regulatory procedures, supplementary protection certificate status, and local reimbursement. Japan and other Asian markets may place greater emphasis on dosage-form convenience and hospital or specialist prescribing channels.

What generic launch risks exist for REYVOW?

A generic lasmiditan tablet is technically feasible because the reference product is an immediate-release solid oral dosage form with conventional excipients. The main risks are patent timing, bioequivalence, API supply, CNS labeling, and the limited size of the addressable market.

Generic price erosion could be rapid if multiple applicants enter simultaneously. A first generic may gain a temporary advantage through earlier approval or settlement-based entry, but long-term differentiation would be limited unless the product uses a distinctive strength, package, or patient-support program.

A 505(b)(2) ODT or film could avoid direct price competition with standard tablets, but it would require greater investment and clinical-regulatory justification.

Key Takeaways

• REYVOW is an immediate-release lasmiditan tablet available in 50 mg and 100 mg strengths.
• Public labeling identifies lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, and magnesium stearate as core excipients.
• The strongest formulation opportunities are lactose-free tablets, ODTs, oral films, and packaging designed for acute migraine use.
• CNS adverse effects and the eight-hour driving restriction limit the value of formulations that sharply increase peak exposure.
• A conventional generic tablet is more feasible than a differentiated oral film or modified-release product.
• A 505(b)(2) ODT or film could create more commercial separation than an excipient-only tablet change.
• Patent value is likely greatest in composition-of-matter, solid-form, process, and clinically supported formulation claims.
• Lilly’s public financial reporting does not provide a separately disclosed REYVOW revenue figure.
• Gepants, especially rimegepant and zavegepant, create the most relevant delivery-system competition.

FAQs

Can REYVOW be reformulated without changing the active ingredient?

Yes. A sponsor can change fillers, binders, disintegrants, lubricants, coatings, or dosage-form architecture, subject to FDA requirements for bioequivalence, safety, quality, and labeling.

Is a lactose-free lasmiditan tablet commercially attractive?

Yes, but mainly as a secondary differentiation strategy. Lactose removal alone is unlikely to support a premium unless combined with improved swallowability, smaller tablet size, or a strong generic substitution strategy.

Would an REYVOW ODT eliminate the eight-hour driving restriction?

No. The restriction is linked to lasmiditan’s CNS effects, not to the tablet’s physical form.[1]

Is an oral film likely to be easier to develop than an ODT?

No. An oral film may offer better portability, but it creates larger technical challenges in dose loading, taste masking, moisture control, film uniformity, and commercial manufacturing.

What is the most defensible excipient-related patent position?

A claim supported by comparative data showing a defined dissolution, stability, particle-engineering, or pharmacokinetic advantage is stronger than a broad claim listing routine excipients.

References

1. U.S. Food and Drug Administration. (2019). REYVOW (lasmiditan) tablets, prescribing information. Eli Lilly and Company.

2. U.S. Food and Drug Administration. (2019). NURTEC ODT (rimegepant sulfate) orally disintegrating tablets, prescribing information. Biohaven Pharmaceuticals.

3. U.S. Food and Drug Administration. (2023). ZAVZPRET (zavegepant) nasal spray, prescribing information. Pfizer Inc.

4. U.S. Food and Drug Administration. (2019). Drugs@FDA: REYVOW application and approval history, NDA 211280. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

6. United States Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

8. Eli Lilly and Company. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investor.lilly.com/financial-information/sec-filings